Nestec S.a.

Societe Des Produits Nestle S.a.

Olivier Ballevre

Clara L. Garcia-rodenas

Florence Rochat

Roberto Reniero

Jalil Benyacoub

Eduardo Schiffrin

Thierry Von Der Weid

Jean-Richard Neeser

Ralf Zink

Pablo Perez

Christoph Cavadini

Alain Servin

Stephanie Blum-Sperisen

Norbert Sprenger

Clara Lucia Garcia-Rodenas

Claudia Roessle

Helen Gillian Anantharaman

Virginie Rousseau

Annick Mercenier

Denis Breuille

Norman Alan Greenberg

Dominique Brassart

Magali Faure

Marie-Claire Fichot

Laurent Favre

Jennifer Rae Mager

Harald Bruessow

Alfred Jann

Corinne Lesens

Andrea M Pfeifer

Stephane Duboux

Ferdinand Haschke

Zdenek Kratky

Marco Enrico Turini

Gabriela Bergonzelli Degonda

Thierry Der Weid

Irène Corthesy-Theulaz

Karl-Josef Huber-Haag

Francis Foata

Christine Cherbut

Sami Damak

Daniel Schmid

Marie-Christine Secretin

Gabriela Bergonzelli

Zamzam Fariba Roughead

Harriet Link

Olivier Mignot

Julie Ann Swanson

Zamzam (Fariba) Roughead

Anne Donnet

Douglas Richard Bolster

Ruth Knorr

Stephanie Blum-Speriesen

Irene Corthesy Theulaz

Virginia Rousseau

Clara Lucia Garcia Rodenas

Christian Dufort

Yves Guigoz

Andreas Rytz

Lisa Marcela Lamothe

Anne-Lise Carrie

Eva Arrigoni

Rosa ARAGÃO BÖRNER

Claire Laurence Lucie Marie Boulange

Jane Mea M Natividad

Christina Ammann

Stéphanie Blum-Sperisen

Harriet Link-Amster

Anne Bauche

Lukas Van Oudenhove

Kristin Verbeke

Clara L Garcia-Rodenas

The present invention relates to aprobiotic for use to improve fermentability of a plant fibre during gastro-intestinal tract passage in a subject, wherein said plant fibre has an insoluble fraction of between 40 to 80% (w/w).

Insoluble fibre fermentability and short chain fatty acid production by

The present invention relates to nutritional compositions comprising 2'-Fucosyllactose (2′FL) for use in improving the gastrointestinal barrier. In particular, the present invention relates to improving gastrointestinal barrier in an infant, a young child or children aged above 3 years to 8 years.

Nutritional composition comprising 2'-Fucosyllactose (2′ FL) to improve the gastrointestinal barrier

The present invention relates to a nutritional composition comprising at least two human milk oligosaccharides, for use to decrease the concentration of detrimental proteolytic metabolites (e.g. branched short chain fatty acids) in the digestive tract in an infant or a young child.

Methods and compositions for decreasing concentrations of detrimental proteolytic metabolites, treating health disorders, and/or promoting health benefits in infants or young children

The present invention relates to a nutritional composition comprising at least three human milk oligosaccharides, for use to increase butyrate production in the digestive tract in an infant or a young child. The production increases with the HMOs blend complexity.

Synergistic production of butyrate associated with the complexity of HMOS blend for use in infants or young children for health purposes

The present invention relates to the use of probiotic on expecting female mammals to boost the immune status of an offspring. The use can induce an enhanced response of the offspring after birth to an infectious antigenic exposure. Ultimately the use of probiotic in expecting females can induce a better protection of their offspring against infectious diseases.

Probiotics for use in expecting female mammals for enhancing the immunity of their offspring

Nutritional compositions are provided that comprise a fructo-oligosaccharaide (FOS) in an amount of 35 to 44% by weight; a polysaccharide that is not a partially hydrolyzed guar gum such as, for example, an arabinogalactan in an amount of 50% to 38% by weight; and inulin in an amount of 12% to 24% by weight. The FOS and the polysaccharide may be present in a weight ratio of about 1:1. More specifically, the FOS and inulin may be present in a weight ratio of about 7:3. Also provided are methods of promoting gut micro biota balance and health. The methods include administering an effective amount of the nutritional composition to patients in need of same.

Nutritional composition for promoting gut microbiota balance and health

A nutritional composition is used to reconstitute an optimal healthy microbiota ecosystem in humans or animals. In particular, an ingestible carrier contains specific amino acids designed to favor the growth of bacteria favorable to individuals health or for reducing the risk of developing deleterious events. In another aspect, specific amino acids are used to reconstitute an optimal healthy microbiota ecosystem in humans or animals, in particular in infants, critically ill patients, in the case of chronic diseases or any stresses impacting the gut and in elderly people.

Amino acid supplementation for a healthy microbiota ecosystem

The invention relates to the use, in the manufacture of a medicament or a therapeutic nutritional composition for preventing or reducing inflammation in a mammal, ofATCC BAAA-999.

[object Object]

The present invention relates to the use of probiotic on expecting female mammals to boost the immune status of offspring. The use can induce an enhanced response of the offspring after birth to an infectious antigenic exposure. Ultimately the use of probiotic in expecting females can induce a better protection of offspring against infectious diseases.

Probiotics for use in expecting female mammals for enhancing the immunity of their offsprings

The present invention pertains to a nutritional composition for reconstituting an optimal healthy microbiota ecosystem in humans or animals. In particular, the present invention relates to an ingestible carrier containing specific amino acids designed to favor the growth of bacteria favorable to individuals health or for reducing the risk of developing deleterious events. The invention also pertains to the use of specific amino acids for reconstituting an optimal healthy microbiota ecosystem in humans or animals, in particular in infants, critically ill patients, in the case of chronic diseases or any stresses impacting the gut and in elderly people.

The present disclosure relates to nutritional compositions comprising a fructo-oligosaccharide (FOS) in an amount of 35 to 44% by weight; a polysaccharide that is not a partially hydrolyzed guar gum such as, for example, an arabinogalactan in an amount of 50% to 38% by weight; and inulin in an amount of 12% to 24% by weight. The FOS and the polysaccharide may be present in a weight ratio of about 1:1. More specifically, the FOS and inulin may be present in a weight ratio of about 7:3. Also provided are methods of promoting gut microbiota balance and health. The methods include administering an effective amount of the nutritional composition to patients in need of same.

Methods for promoting gut microbiota balance

The use of a whey predominant protein source and lactose in the manufacture of a nutritional composition for promoting the development of an early bifidogenic intestinal microbiota in infants fed with the nutritional composition wherein the nutritional composition has a protein content of less than 2.1 g protein/100 kcal and a phosphorus content of less than 40 mg/100 kcal.

Gut microbiota in infants

Use of probiotic bacteria in the manufacture of a medicament or therapeutic nutritional composition for increasing IgA secretion in an infant delivered by cesarean section during the first four months of the life of the infant.

Probiotics to increase IgA secretion in infants born by Caesarean section

The invention relates to the use, in the manufacture of a medicament or a therapeutic nutritional composition for preventing or reducing inflammation in a mammal, ofATCC BAA-999.

The present invention provides novel strains of probiotics for use in the gastrointestinal tract of a pet. The probiotics of the present invention are capable of fermenting starch to produce lactic acid and/or hydrogen peroxide anti-pathogenic metabolites. The present invention also provides a novel method for identifying the effectiveness of a pet probiotic in vitro. The method simulates the introduction of a probiotic candidate in the gastrointestinal tract of a pet and measures the anti-pathogenic effectiveness of the probiotic.

Probiotic strains for pets

Growing community of inventors

Montreux, Switzerland

Florence Rochat